10-K: NRx Pharmaceuticals Advances Drug Pipeline, Expands HOPE Network Amidst Going Concern Warning

NRx Pharmaceuticals reports significant progress in its neuroplasticity drug pipeline and the expansion of its interventional psychiatry subsidiary, HOPE Therapeutics, despite facing substantial financial losses and a going concern warning.

Summary

• NRx Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing novel therapeutics for central nervous system disorders, including suicidal depression, chronic pain, PTSD, and schizophrenia.
• The company's lead drug candidates include NRX-100 (preservative-free intravenous ketamine), KETAFREE (generic preservative-free ketamine), and NRX-101 (oral fixed-dose combination of D-cycloserine and lurasidone).
• An Abbreviated New Drug Application (ANDA) for KETAFREE was filed in September 2025, with the FDA identifying no significant deficiencies in November 2025 and no bioequivalence deficiencies in March 2026; commercial sales are anticipated in Q3 2026, targeting a generic market exceeding $750 million annually.
• A New Drug Application (NDA) for NRX-100 is expected to be filed in Q2 2026, following the award of Fast Track Designation for 'Treatment of Suicidal Ideation in Depression, including Bipolar Depression,' which expands the addressable market to 13 million Americans.
• The FDA has agreed to review existing clinical trials and Real World Evidence (RWE) from 65,000 patients for NRX-100, with interim analysis suggesting IV ketamine may have a more rapid onset and larger effect than nasal S-ketamine (SPRAVATO, with estimated sales of ~$2 billion/year).
• An NDA filing for NRX-101 has been initiated with the submission of Module 3 manufacturing data, leveraging its Breakthrough Therapy Designation for accelerated approval in bipolar depression with suicidal ideation and akathisia.
• A new indication for NRX-101 involves augmenting Transcranial Magnetic Stimulation (TMS), with a protocol filed with the FDA to test its use with the ONE-D TMS protocol, potentially offering rapid remission from severe depression and PTSD.
• HOPE Therapeutics, a medical services subsidiary, generated its first clinical revenue in Q4 2025, following the acquisition of Dura Medical, LLC in September 2025, and currently operates in five Florida locations with plans to expand to eight or more by Q2 2026.
• The company reported a net loss of $28.6 million for the year ended December 31, 2025, compared to $25.1 million in 2024.
• As of December 31, 2025, cash and cash equivalents were $7.8 million, with an accumulated deficit of $306.9 million and a stockholders' deficit of $15.9 million.
• The company's auditors have expressed substantial doubt about its ability to continue as a going concern.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this filing with cautious optimism. While significant progress in drug development and FDA designations are positive, the company's substantial and increasing net losses, ongoing need for capital, and the explicit 'going concern' warning from auditors present considerable financial risks. The operational growth of HOPE Therapeutics is a positive, but its revenue is currently minimal compared to the company's burn rate.

Positives

• KETAFREE ANDA received preliminary determination of no bioequivalence deficiency from FDA, with commercial sales anticipated in Q3 2026, targeting a $750 million generic market.
• NRX-100 received expanded Fast Track Designation for 'Treatment of Suicidal Ideation in Depression, including Bipolar Depression,' representing a 10-fold market expansion to 13 million Americans.
• FDA agreed to review existing clinical trials and Real World Evidence (RWE) for NRX-100, potentially leading to full NDA approval without new trials.
• Interim RWE analysis for IV ketamine suggests more rapid onset and larger effect than nasal S-ketamine.
• NRX-101 has Breakthrough Therapy Designation and is seeking accelerated approval for suicidal bipolar depression with akathisia.
• Promising new indication for NRX-101 to augment TMS, with potential for rapid remission from severe depression and PTSD. Clinical trial for this indication anticipated in Q2 2026 with potential non-dilutive government funding.
• HOPE Therapeutics generated its first clinical revenue in Q4 2025 and is expanding its clinical footprint, operating in five Florida locations with plans for eight+ by end of Q2 2026.
• Acquisition of Dura Medical, LLC made HOPE a revenue-generating clinical enterprise.
• Appointment of Professor Joshua Brown, MD, PhD, as Chief Medical Innovation Officer for HOPE Therapeutics.
• NRx-100 and KETAFREE manufacturing steps completed, with stability data supporting a three-year room temperature shelf life.
• Filing fee waiver received from the FDA for NRX-100.
• The company has a patent filing for its proprietary, preservative-free formulation of ketamine, which could confer market exclusivity.

Negatives

• The company has a limited operating history and has incurred significant operating losses since inception, with a net loss of $28.6 million in 2025.
• Substantial doubt exists about the company's ability to continue as a going concern for at least twelve months from the financial statement issuance date.
• Requires substantial additional capital to fund continuing operations, product development, and potential commercialization in 2026.
• NRX-101 is still in Phase 2/3 clinical testing, and manufacturing has not yet scaled to levels required for sustained sales.
• The company is reliant on third-party manufacturers, exposing it to risks of non-compliance or delays.
• The use of controlled substances (ketamine in NRX-100) subjects the company to DEA scrutiny and quota limitations, which could impact supply.
• The Kadima Acquisition has not closed and is in arbitration, with an uncertain outcome.
• The company's common stock price is likely to be volatile, and future equity issuances could dilute existing shareholders.
• No cash dividends are anticipated in the foreseeable future.
• The company has a stockholders' deficit of $15.9 million and a working capital deficit of $19.7 million as of December 31, 2025.

Risks

• Operating results and financial condition may fluctuate from period to period.
• Limited operating history upon which to base an investment decision.
• Need to raise additional capital to operate the business; failure to obtain capital could lead to inability to continue as a going concern.
• NRX-101 is still in Phase 2/3 clinical testing.
• Manufacturing of drug products has not yet scaled to levels required for sustained sales.
• Outcome of current or future disputes, claims, arbitration, and litigation could have a material adverse effect.
• Failure to obtain or maintain FDA and other regulatory clearances for products, or delays in such clearances, would prevent commercial distribution and marketing.
• Products will face significant competition; inability to compete successfully will harm the business.
• Global economic, political, and social conditions, armed conflicts, and market uncertainties may adversely impact the business.
• Relationships with potential customers and payors will be subject to anti-kickback, fraud and abuse, transparency, and other healthcare laws and regulations, potentially leading to criminal sanctions, civil penalties, and reputational harm.
• Managing growth as operations expand may strain resources.
• Future acquisitions or strategic transactions may require additional financing, increase expenses, and distract management.
• Inability to identify, audit, negotiate, finance, or close future acquisitions.
• Failure to achieve and maintain effective internal controls over financial reporting could impair ability to produce timely and accurate financial statements.
• Even if a drug product is approved, regulators may impose limitations on its use or marketing.
• Inability to design, conduct, and complete clinical trials successfully would prevent regulatory approval.
• No guarantee that regulators will grant NDA approval; failure to obtain approvals would adversely affect business growth.
• Regulatory authorities' discussions and guidance are not binding obligations.
• Clinical trial results may not support product candidate claims or may reveal unexpected adverse side effects.
• Delays in pharmaceutical development, manufacturing, or clinical testing could increase costs and delay revenue generation.
• Difficulty in identifying and recruiting suitable patients for large clinical trials.
• Inadequate development of clinical protocols to demonstrate safety and efficacy.
• Modifications to clinical trial protocols may cause delays or render data unacceptable to regulators.
• Adverse events during clinical trials could lead to delays or termination.
• Even if products are approved, failure to comply with ongoing FDA regulation or unanticipated product problems could lead to restrictions or market withdrawal.
• Future government regulation may affect commercialization.
• Limitations on the availability of controlled substances (ketamine) may limit active ingredient supply.
• Failure to comply with environmental, health, and safety laws and regulations could result in fines or penalties.
• Use of controlled substances in product candidates may generate controversy.
• Reliance on third-party manufacturers to produce controlled substances.
• Business relies on certain licensing rights that can be terminated.
• May not succeed at in-licensing drug candidates or technologies.
• Business depends upon securing and protecting critical intellectual property.
• Patent position is highly uncertain and involves complex legal and factual questions.
• Involvement in lawsuits to protect or enforce patents could be expensive, time-consuming, and unsuccessful.
• Limited foreign intellectual property rights.
• Ability to protect and enforce patents does not guarantee commercialization rights.
• May not receive royalty or milestone revenue relating to product candidates for several years, or at all.
• No direct control of third parties performing preclinical and clinical trials.
• No manufacturing capabilities and dependence on other parties for manufacturing operations.
• Dependence on partners to assist in commercializing product candidates.
• Upon commercialization, dependence on third parties to market, distribute, and sell products.
• Issuance of additional shares of common stock or convertible securities could make acquisition difficult, dilute ownership, and adversely affect stock price.
• Qualifying as a smaller reporting company may make securities less attractive to investors.
• Anti-takeover provisions in governing documents and Delaware law could make an acquisition more difficult.
• Delaware Court of Chancery as the sole and exclusive forum for substantially all disputes.
• Certain stockholders have effective control, and their interests may conflict.
• Common stock price may be volatile or may decline regardless of operating performance.
• Securities litigation could have a substantial cost and divert resources.
• Lack of analyst coverage or unfavorable reports could cause stock price to decline.
• Obligations associated with being a public company will involve significant expenses and require significant resources and management attention.
• Failure to meet Nasdaq continued listing requirements could lead to delisting.

Future Outlook

The company anticipates initiating commercial sales of KETAFREE in Q3 2026 and entering the innovative market for ketamine in late 2026. An NDA for NRX-100 is expected to be filed in Q2 2026, with the FDA guiding towards full NDA approval and a broader indication for severe depression with suicidal ideation. An NDA filing for NRX-101 has been initiated, seeking accelerated approval for bipolar depression with suicidal ideation and akathisia. A new Phase 2b/3 trial for NRX-101 augmenting TMS is anticipated to start in Q2 2026, with potential non-dilutive government funding, and could lead to a 2027 PDUFA date for this indication. HOPE Therapeutics expects to expand to eight or more locations by the end of Q2 2026 and projects incremental revenue from clinical operations and future pharmaceutical product sales. Management believes it will secure necessary financing to support acquisitions and business plans.

Management Comments

• Management believes that it will be able to secure necessary financing to support and consummate both its previously announced acquisitions and potential future acquisition candidates, execute its business plan and achieve its projected revenue objectives.
• Management anticipates that revenue will increase in subsequent periods as Duras operations are fully integrated and additional clinical capacity, patient volume, and service lines are expanded under the Company's ownership.
• Management believes that a preservative-free form of ketamine will be welcomed by physicians and patients, which may enable NRX-100 to gain a larger share of the existing ketamine market than would be available to an undifferentiated product.
• The Company is aware of no impediments to an acceptance of the ANDA package and anticipates regulatory action in the summer of 2026.
• FDA guided the Company to seek full NDA approval, rather than accelerated approval for NRX-100. FDA further guided the Company to broaden the indication for NRX-100 to patients with severe depression (including bipolar depression) who may have suicidal ideation rather than the smaller population of those who have active suicidal ideation. FDA agreed to review patient-level data from already-completed clinical trials for Substantial Evidence of Efficacy and did not ask the Company to conduct additional clinical trials. FDA further agreed to review Real World Evidence developed in partnership with Osmind, Inc. as confirmatory evidence of efficacy.
• NRX-101 is the only oral medicine that has ever been demonstrated in two randomized trials to reduce active suicidality and akathisia, to the Company's knowledge.
• Based on the rapid adoption of accelerated TMS and the dramatic results seen, we estimate that between 1 and 3 million Americans will receive TMS for depression annually.
• The CODM does not separately evaluate performance by geographic region or product line, as the Company has limited operations due to the current liquidity and funding of the Company.

Industry Context

StockSavvy.ai notes that NRx Pharmaceuticals operates in the highly competitive and rapidly evolving biopharmaceutical industry, particularly in central nervous system disorders. The focus on NMDA receptor modulation aligns with emerging trends in neuroplasticity-enhancing treatments for mental health. The company's strategy to combine drug development with a clinical care delivery network (HOPE Therapeutics) positions it uniquely to capture value across the treatment spectrum, from drug manufacturing to patient services. The pursuit of preservative-free ketamine addresses a potential safety concern in the existing generic market, while the integration of NRX-101 with TMS taps into a growing market for neuromodulatory devices. The estimated $750 million generic ketamine market and $2 billion S-ketamine market highlight significant commercial opportunities if regulatory approvals are secured.

Comparison to Industry Standards

• NRX-100's potential for full NDA approval based on existing clinical trials and RWE, without requiring new trials, is a significant advantage compared to typical drug development pathways that often necessitate extensive new Phase 3 studies.
• The interim RWE analysis suggesting IV ketamine's more rapid onset and larger magnitude of effect compared to intranasal S-ketamine (SPRAVATO, with estimated sales of $2 billion/year) indicates a potentially superior product profile.
• NRX-101 is highlighted as the 'only oral medicine that has ever been demonstrated in two randomized trials to reduce active suicidality and akathisia,' setting a unique standard in its target indication.
• The ONE-D TMS protocol, combined with D-cycloserine (key ingredient in NRX-101), demonstrated 87% response and 72% remission from severe depression at 6 weeks after a single day of treatment, which is a dramatically higher and faster response rate than many conventional antidepressant therapies.
• The company's strategy to acquire and integrate interventional psychiatry clinics (e.g., Dura Medical, Cohen & Associates) is a vertical integration approach that differs from many pure-play biopharmaceutical companies, aiming to control both drug development and delivery.

Management Changes

Corporate Governance

Legal Proceedings

• Relief Therapeutics Lawsuit: Settled on November 12, 2022, with an Asset Purchase Agreement. Claims dismissed on December 17, 2022.
• GEM Arbitration: Demand for arbitration received August 12, 2022, for HK$15,000,000 commitment fee. Settled on July 17, 2023, by issuing 67,568 shares of common stock to GEM on August 31, 2023.
• Streeterville Capital, LLC Litigation: Lawsuit seeking to enjoin a spin-off and repayment of a note. Arbitrator denied petition to enjoin spin-off on July 29, 2024. Settled on August 12, 2024, for payments of $2.5 million (August 15, 2024) and $3.05 million (October 2024).
• Kadima Acquisition Arbitration: HOPE and HTX entered an Asset Purchase and Contribution Agreement on May 9, 2025. Acquisition has not closed and is in arbitration. Too early to determine material adverse effect.

Related Party Transactions

• Glytech LLC (owned by Daniel Javitt, brother of Jonathan Javitt): Licenses patents to the company. Paid $0 in 2025 and $0.3 million in 2024 for technology support services and reimbursed expenses. An amendment in December 2020 includes an equity value-triggered transfer of Excluded Technology to the company upon certain conditions.
• Dr. Jonathan Javitt (Chairman, CEO, Chief Scientist): Received $0.8 million in compensation in 2025 and $0.1 million in 2024 under a consulting agreement. Eligible for an annual performance-based bonus ($0.2 million accrued in 2025 and 2024).
• Zachary Javitt (son of Dr. Jonathan Javitt): Provides website, IT, and marketing support. Paid $0.2 million in 2025 and $0.1 million in 2024.
• Michael Taylor (Director): Entered into a consulting agreement in June 2024 for capital formation and strategic advisory services for HOPE Therapeutics. Paid $120 thousand in 2025 and $100 thousand in 2024.
• Dura Properties, LLC (owned by Dura's former sole member, now a director/minority shareholder): The company leases its Naples clinic from this entity. Total payments of approximately $29 thousand in 2025.

Stakeholder Impact

• Shareholders: Potential for significant dilution from ongoing capital raises. Volatility in stock price is expected. The 'going concern' warning poses a substantial risk to investment value. Potential for future value creation if drug candidates are approved and commercialized successfully, and if HOPE Therapeutics expands profitably.
• Employees: Continued employment and potential equity compensation are tied to the company's financial stability and success. Management changes and growth of HOPE Therapeutics could create new opportunities.
• Patients: Potential for new therapeutic options for serious CNS disorders (suicidal depression, PTSD, chronic pain, schizophrenia) if drug candidates receive regulatory approval. HOPE Therapeutics aims to provide cutting-edge interventional psychiatry care.
• Creditors: The 'going concern' warning and substantial debt obligations (convertible notes) indicate elevated risk for creditors.
• Regulatory Bodies: Ongoing engagement with FDA for drug approvals and compliance with SEC reporting requirements.

Next Steps

• Initiate commercial sales of KETAFREE with FDA approval in Q3 2026.
• File New Drug Application (NDA) for NRX-100 in Q2 2026.
• Continue NDA filing for NRX-101 with rolling review.
• Initiate clinical trial for NRX-101 in conjunction with ONE-D TMS protocol in Q2 2026.
• Expand HOPE Therapeutics operations to eight or more locations by the end of Q2 2026.
• Secure necessary financing to support ongoing operations, acquisitions, and business plans in 2026.
• Finalize the purchase price allocation for the Dura acquisition within the one-year measurement period.
• Resolve the arbitration for the Kadima Acquisition.
• Address Nasdaq listing compliance regarding the annual meeting.

Key Dates

Recommendation

NRx Pharmaceuticals presents a high-risk, high-reward investment profile. The company has made significant progress in advancing its drug candidates (KETAFREE, NRX-100, NRX-101) through FDA regulatory pathways, including Fast Track and Breakthrough Therapy designations, and has initiated revenue generation through HOPE Therapeutics. These operational achievements and the large addressable markets for its pipeline drugs are compelling. However, the company's substantial and increasing net losses, negative cash flow from operations, and the explicit 'going concern' warning from its auditors highlight severe liquidity challenges and a heavy reliance on future capital raises. While the potential for non-dilutive government funding for a key trial is positive, the overall financial instability warrants a 'hold' recommendation. Investors should monitor the company's ability to secure additional financing, achieve regulatory approvals, and scale commercial operations before considering a 'buy' rating. The stock is highly speculative.

Keywords

Biopharmaceutical, Central Nervous System, Suicidal Depression, Chronic Pain, PTSD, Schizophrenia, Ketamine, NRX-100, KETAFREE, NRX-101, D-cycloserine, Lurasidone, NMDA receptor, Neuroplasticity, HOPE Therapeutics, Interventional Psychiatry, Transcranial Magnetic Stimulation (TMS), FDA Approval, Fast Track Designation, Breakthrough Therapy Designation, Real World Evidence (RWE), NDA, ANDA, Clinical Trials, Corporate Governance, Cybersecurity, Capital Raise, Going Concern